Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
15 sept. 2020 08h07 HE
|
Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
03 sept. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium Announces Closing of Public Offering of Common Stock
18 août 2020 16h05 HE
|
Equillium
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Pricing of Public Offering of Common Stock
13 août 2020 21h42 HE
|
Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Proposed Public Offering of Common Stock
13 août 2020 16h02 HE
|
Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
12 août 2020 08h37 HE
|
Equillium
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
10 août 2020 16h07 HE
|
Equillium
Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA LA JOLLA, Calif., Aug. 10, 2020 (GLOBE...
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
30 juil. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
13 juil. 2020 03h30 HE
|
Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
Equillium to Present at Jefferies Virtual Healthcare Conference
21 mai 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...